PL BioScience GmbH has successfully completed a Series A financing round. The growth financing round attracted significant investments from AVANT BIO (New York), LePure Biotech (Shanghai), b.value AG (Dortmund) and better ventures (Munich). The four partners contribute their experience in deep tech, life sciences and health tech.

。这轮增长融资吸引了先锋生物（纽约）、乐普尔生物技术（上海）、b.value AG（多特蒙德）和better ventures（慕尼黑）的大量投资。这四个合作伙伴贡献了他们在深度技术、生命科学和健康技术方面的经验。

The consortium joins a group of existing investors led by Brightlands Venture Partners (Geleen) and TechVision Fonds (Aachen), who have once again pledged their support for the Aachen-based biotech company's mission. PL BioScience's Human Platelet Lysate (HPL) technology enables breakthrough developments in cell therapy.

该财团加入了由Brightlands Venture Partners（Geleen）和TechVision Fonds（亚琛）领导的现有投资者小组，他们再次承诺支持这家总部位于亚琛的生物技术公司的使命。PL BioScience的人血小板裂解物（HPL）技术实现了细胞治疗的突破性发展。

'We look forward to continuing our support for PL BioScience and its outstanding HPL products in the coming years together with this great consortium of investors,' says Bernhard Kugel, Managing Partner of the TechVision Fund. Dr. Luc Starmans, Partner at Brightlands Venture Partners, also expresses his continued commitment: 'We warmly congratulate the team and welcome our new partners on this exciting journey.

TechVision基金管理合伙人伯恩哈德·库格尔（BernhardKugel）表示：“我们期待着在未来几年继续与这一庞大的投资者财团一起支持PL BioScience及其出色的HPL产品。”。Brightlands Venture Partners的合伙人Luc Starmans博士也表达了他的持续承诺：“我们热烈祝贺团队，并欢迎我们的新合作伙伴踏上这段激动人心的旅程。

Together, we look forward to building on PL BioScience's groundbreaking work to advance effective cell therapies that will bring transformative benefits to both patients and the planet.' .

总之，我们期待着在PL BioScience的开创性工作的基础上，推进有效的细胞疗法，为患者和地球带来变革性的益处。”

Pioneering cell culture technology from Aachen

亚琛开创性的细胞培养技术

HPL is derived from donated blood that is no longer suitable for transfusion and offers a sustainable and effective alternative to animal-derived cell culture media. Conventional methods often use fetal calf serum (TCS), which is obtained from the blood of calf fetuses. With HPL, a more seamless transferability of research results to humans is possible.

HPL来源于不再适合输血的捐赠血液，为动物来源的细胞培养基提供了一种可持续有效的替代品。常规方法通常使用胎牛血清（TCS），它是从小牛胎儿的血液中获得的。有了HPL，研究结果可以更无缝地传递给人类。

The technology ensures reliable results in laboratories worldwide, paving the way for major advances in regenerative medicine. .

该技术确保了全球实验室的可靠结果，为再生医学的重大进步铺平了道路。

Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of current news. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar.

注意：本文已使用计算机系统翻译，无需人工干预。LUMITOS提供这些自动翻译，以呈现更广泛的当前新闻。由于本文是自动翻译的，因此它可能包含词汇、语法或语法错误。

The original article in German can be found here..

德语原文可以在这里找到。

https://www.bionity.com/en/news/1184156/animal-free-cell-therapy-from-aachen-secures-global-growth.html

https://www.bionity.com/en/news/1184156/animal-free-cell-therapy-from-aachen-secures-global-growth.html